# Why Long Term Acne Studies Are Rare
Acne affects a significant portion of the population, with research showing that about 85% of adolescents experience the condition. Despite how common acne is, long-term studies tracking its progression and treatment outcomes remain surprisingly limited. Understanding why these studies are difficult to conduct reveals important challenges in dermatological research.
One major obstacle is the nature of acne itself. The condition involves complex biological processes across multiple systems in the body. Researchers have identified approximately 50 genetic risk loci associated with acne, with genes influencing hair follicle development, sebaceous gland structure, lipid metabolism, and stem cell behavior. This genetic complexity means that studying acne requires examining many different biological pathways simultaneously, making research more expensive and time-consuming than studying simpler conditions.
The lack of standardized severity grading systems creates another significant barrier. When researchers try to compare results across different studies, they encounter a fundamental problem: there is no reliable consensus on how to measure and classify acne severity. This inconsistency makes it difficult to combine data from multiple studies or to track how patients progress over time using comparable metrics. Without standard measurement tools, long-term studies become harder to design and their results become harder to interpret alongside other research.
Patient populations present their own challenges for longitudinal research. College-age individuals, who represent a significant portion of acne patients, have not yet developed stable psychological cognition and may be more likely to drop out of long-term studies. Additionally, many acne studies have focused primarily on populations in Europe and the United States, leaving gaps in understanding how the condition affects people in other regions and demographic groups. This geographic limitation means researchers cannot easily generalize findings across different populations.
The multifactorial nature of acne also complicates long-term tracking. Research has identified numerous potential risk factors including stress, hormonal changes, environmental pollution, residential location changes, and lifestyle factors. However, establishing clear causal relationships between these factors and acne severity requires careful, prolonged observation. The difficulty in isolating which factors truly matter means that comprehensive long-term studies must account for many variables simultaneously, increasing complexity and cost.
Current therapeutic limitations further discourage extensive long-term research. Even the best available treatments often fail to provide lasting responses in all patients. Some individuals never respond to standard therapies, while others lose effectiveness over time. This variability means that tracking treatment outcomes across years becomes complicated, as researchers must account for treatment failures, switches between medications, and varying patient compliance. The lack of universally effective treatments makes it harder to design studies with clear endpoints.
The field is beginning to recognize that meaningful progress requires integrating multiple types of data collected over extended periods. This includes genetic information, gene expression patterns, protein analysis, metabolic data, clinical observations, imaging results, digital measurements from wearable devices, and patient-reported experiences. Combining all these measurement types in a single long-term study demands significant resources, specialized equipment, and coordinated teams of researchers. Most institutions and funding sources cannot support such comprehensive, prolonged investigations.
Additionally, the psychological impact of acne on patients, particularly adolescents, creates ethical considerations for long-term studies. Researchers must balance the scientific value of extended observation against the potential harm of withholding effective treatments from control groups or following patients through extended periods of active disease. These ethical constraints limit how long studies can run and how many participants can be enrolled.
The field of dermatology is moving toward recognizing these challenges. Recent advances in 2025 have highlighted the need for better understanding of disease trajectories through longitudinal and spatial analyses. Researchers are increasingly aware that tracking how immune cells and skin structures change over time in individual patients could identify which therapeutic targets matter most. However, translating this awareness into actual long-term studies requires overcoming the practical, financial, and methodological barriers that have historically made such research rare.
Sources
https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2025.1752852/full
https://pmc.ncbi.nlm.nih.gov/articles/PMC12688717/
https://www.dermatologytimes.com/view/dermatology-times-2025-year-in-review-acne
https://dermondemand.com/blog/does-accutane-stunt-growth/
https://academic.oup.com/skinhd/advance-article/doi/10.1093/skinhd/vzaf090/8407371?searchresult=1
